TARA Stock Forecast 2025-2026
Distance to TARA Price Targets
TARA Price Momentum
10 Quality Stocks Worth Considering Now
Researching ArTara (TARA) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on TARA and similar high-potential opportunities.
Latest TARA Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, TARA has a bullish consensus with a median price target of $24.00 (ranging from $22.00 to $30.00). The overall analyst rating is Strong Buy (9.6/10). Currently trading at $4.73, the median forecast implies a 407.4% upside. This outlook is supported by 5 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Leland Gershell at Oppenheimer, projecting a 534.2% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
TARA Analyst Ratings
TARA Price Target Range
Latest TARA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for TARA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 14, 2025 | Cantor Fitzgerald | Li Watsek | Overweight | Initiates | $0.00 |
| Mar 11, 2025 | LifeSci Capital | Outperform | Initiates | $22.00 | |
| Mar 6, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $23.00 |
| Dec 6, 2024 | Guggenheim | Michael Schmidt | Buy | Reiterates | $20.00 |
| Dec 6, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $23.00 |
| Nov 14, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $23.00 |
| Aug 12, 2024 | Oppenheimer | Leland Gershell | Outperform | Maintains | $25.00 |
| Aug 8, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $23.00 |
| May 6, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $23.00 |
| Apr 22, 2024 | Oppenheimer | Leland Gershell | Outperform | Maintains | $30.00 |
| Apr 8, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Maintains | $23.00 |
| Mar 14, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $23.00 |
| Aug 4, 2023 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $23.00 |
| Jul 10, 2023 | Guggenheim | Charles Zhu | Buy | Assumes | $22.00 |
| May 8, 2023 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $23.00 |
| May 1, 2023 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $23.00 |
| Mar 9, 2023 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $23.00 |
| Aug 10, 2022 | HC Wainwright & Co. | Andrew Fein | Buy | Maintains | $23.00 |
| May 9, 2022 | HC Wainwright & Co. | Andrew Fein | Buy | Maintains | $30.00 |
| Nov 8, 2021 | Oppenheimer | Leland Gershell | Outperform | Maintains | $34.00 |
Protara Therapeutics Inc. (TARA) Competitors
The following stocks are similar to ArTara based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Protara Therapeutics Inc. (TARA) Financial Data
Protara Therapeutics Inc. has a market capitalization of $172.81M with a P/E ratio of 0.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -37.9%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Protara Therapeutics Inc. (TARA) Business Model
About Protara Therapeutics Inc.
Develops therapies for rare and specialty diseases.
Protara Therapeutics generates revenue by developing innovative therapies targeting rare and specialty diseases, particularly through its lead product, TARA-002, which is designed for treating lymphatic malformations and non-muscle invasive bladder cancer. The company positions itself to address significant unmet medical needs in oncology and other critical areas.
Based in New York, Protara Therapeutics is committed to advancing medical innovation and improving patient outcomes. The company's focus on research and development aims to bridge the gap in treatment options provided by traditional pharmaceuticals, contributing positively to the healthcare landscape.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
28
CEO
Mr. Jesse Shefferman
Country
United States
IPO Year
2014
Website
www.protaratx.comProtara Therapeutics Inc. (TARA) Latest News & Analysis
Protara Therapeutics will present data from its THRIVE-1 study on choline deficiency in parenteral support patients at the ASPEN 2025 Conference, with the THRIVE-3 trial starting in 1H 2025.
Protara Therapeutics’ data presentation and upcoming trial highlight potential market value and innovation in IV nutrition therapies, influencing investor sentiment and company valuation.
Protara Therapeutics reported positive six-month data from the ADVANCED-2 trial for TARA-002 and will provide 12-month data by mid-2025. They have $170 million in cash as of December 31, 2024.
Positive trial results and upcoming data releases indicate potential growth for Protara Therapeutics. Strong cash reserves enhance operational stability and investor confidence in future developments.
Protara Therapeutics will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on March 5, 2025, at 9:50 am ET. A live webcast will be available on their website.
Protara Therapeutics' participation in a major healthcare conference may signal potential investor interest and insights into its pipeline, impacting stock performance and investor sentiment.
Protara Therapeutics reported positive six-month data from its ADVANCED-2 trial for TARA-002 in NMIBC and completed a $100 million public offering. Key trial results are expected in 2025.
Positive trial results and a successful $100 million public offering enhance Protara's financial stability and development prospects, potentially increasing investor confidence and stock value.
Protara Therapeutics: Rising From The Ashes
3 months agoProtara Therapeutics raised $100M at $6.25/share, enhancing valuation post-promising Phase 2 results for TARA-002. Its enterprise value is $70.2M, suggesting significant upside potential.
Protara Therapeutics' promising trial results and new funding enhance its valuation and cash position, suggesting significant upside potential compared to competitors.
Protara Therapeutics closed a public offering of 13.69 million shares at $6.25 each, raising approximately $100 million. Proceeds will fund clinical development and general corporate purposes.
Protara's $100 million stock offering signals funding for clinical development, potentially impacting its growth and stock performance, which could attract or deter investors.
Frequently Asked Questions About TARA Stock
What is Protara Therapeutics Inc.'s (TARA) stock forecast for 2025?
Based on our analysis of 6 Wall Street analysts, Protara Therapeutics Inc. (TARA) has a median price target of $24.00. The highest price target is $30.00 and the lowest is $22.00.
Is TARA stock a good investment in 2025?
According to current analyst ratings, TARA has 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $4.73. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for TARA stock?
Wall Street analysts predict TARA stock could reach $24.00 in the next 12 months. This represents a 407.4% increase from the current price of $4.73. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Protara Therapeutics Inc.'s business model?
Protara Therapeutics generates revenue by developing innovative therapies targeting rare and specialty diseases, particularly through its lead product, TARA-002, which is designed for treating lymphatic malformations and non-muscle invasive bladder cancer. The company positions itself to address significant unmet medical needs in oncology and other critical areas.
What is the highest forecasted price for TARA Protara Therapeutics Inc.?
The highest price target for TARA is $30.00 from Leland Gershell at Oppenheimer, which represents a 534.2% increase from the current price of $4.73.
What is the lowest forecasted price for TARA Protara Therapeutics Inc.?
Price targets from Wall Street analysts for TARA are not currently available. The stock is trading at $4.73.
What is the overall TARA consensus from analysts for Protara Therapeutics Inc.?
The overall analyst consensus for TARA is bullish. Out of 6 Wall Street analysts, 5 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $24.00.
How accurate are TARA stock price projections?
Stock price projections, including those for Protara Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
